The Cancer Therapy That Was Only Supposed to Work in Melanoma Just Showed Up Somewhere New

Lifileucel (sold under the brand name Amtagvi) was the first TIL therapy to get FDA approval, for advanced melanoma in 2024. Melanoma was the obvious first target because it's considered immunologically "hot," meaning the immune system already recognizes it as a threat. TIL therapy just amplifies what the body is already trying to do.

Sarcomas, on the other hand, are the opposite. They're immunologically "cold," tumors that fly under the immune system's radar. Most experts assumed TIL therapy wouldn't work well in these cancers because there might not be enough immune cells infiltrating the tumor to harvest in the first place.

This trial just challenged that assumption.

The Data That Changed the Conversation

The pilot trial, led by Memorial Sloan Kettering Cancer Center, enrolled patients with advanced UPS or DDLPS who had already failed at least one prior treatment. These weren't early-stage patients with small tumors. The average patient had been through more than two prior lines of therapy, and the mean sum of their tumor diameters was 117 millimeters, roughly the length of a smartphone.

Of the first six evaluable patients treated with lifileucel as a standalone therapy, three achieved confirmed objective responses as measured by RECIST v1.1, the standard method for evaluating tumor shrinkage. That's a 50% response rate in a setting where the historical benchmark is below 5%.

Even more encouraging, the responses deepened over time. The tumors didn't just stop growing; they kept shrinking. This pattern mirrors what Iovance has seen with lifileucel in melanoma and non-small cell lung cancer, suggesting TIL therapy might work through a similar mechanism across different tumor types.

The safety profile was consistent with lifileucel's track record in other cancers. No new red flags.

What the Experts Are Saying

Lauren Baker Banks, MD, PhD, a sarcoma specialist at Memorial Sloan Kettering who helped lead the trial, called the results "compelling and unprecedented." She noted that lifileucel "demonstrated compelling and unprecedented response rates with the potential to address a significant unmet need in patients who are refractory to frontline standard of care."

Brian Gastman, Iovance's EVP of Translational Medicine and Research, described the findings as "exciting" and highlighted lifileucel's potential as a "new, highly efficacious, and durable immunotherapy option" in aggressive sarcomas where chemo falls short.

The enthusiasm is understandable. But let's pump the brakes for a second.

The Caveat You Shouldn't Ignore

Six patients is a tiny sample size. You could flip a coin three times and get heads every time; that doesn't mean the coin is rigged. In clinical trials, small numbers can produce eye-popping results that fade as more patients enroll. We've seen this movie before in oncology.

That said, a 50% response rate against a less-than-5% historical baseline is a massive signal, even in a small group. It's the kind of early data that justifies a bigger study, and that's exactly what Iovance is planning.

The company will launch a single-arm registrational trial in second-line UPS and DDLPS in Q2 2026, designed to support an accelerated approval application with the FDA. Single-arm trials, where everyone gets the drug and results are compared against historical benchmarks, are a common path for accelerated approvals in cancers with high unmet need.

The Bigger Picture for Iovance

This sarcoma data doesn't exist in a vacuum. Iovance is building a case that TIL therapy is a platform, not a one-trick pony. Lifileucel already has FDA Fast Track designation for second-line advanced non-small cell lung cancer, where it showed a 25.6% response rate. It's being tested in frontline melanoma alongside pembrolizumab, where early data showed a 65% response rate. Trials in endometrial cancer are underway too.

Financially, the company is in decent shape. Amtagvi revenue from melanoma is growing, gross margins are expanding, and Iovance has enough cash to operate through Q3 2027. That runway matters; it means the sarcoma program won't die from a lack of funding before it gets its shot at approval.

The competitive landscape for TIL therapy is also heating up. Companies like Obsidian Therapeutics are developing next-generation TIL products with built-in enhancements like membrane-bound IL-15 to reduce toxicity. CRISPR-edited TILs and cryopreserved formulations are on the horizon. But for now, Iovance is the only company with an approved TIL product and clinical data in sarcoma.

Why This Matters Beyond Sarcoma

The real significance of this data goes beyond one disease. It's a proof of concept that TIL therapy can work in immunologically cold tumors — the cancers that have largely resisted the checkpoint inhibitor revolution of the last decade.

If you can make TIL therapy work in sarcoma, it opens the door to pancreatic cancer, prostate cancer, and other notoriously difficult-to-treat solid tumors. That's a market measured not in thousands of patients but in hundreds of thousands.

We'll need larger trials and longer follow-up to know if this early promise holds. But for 3,000 Americans diagnosed with UPS and DDLPS every year, a 50% response rate, even a preliminary one, represents something they haven't had in a long time: genuine hope.

The Cancer Drug That Plays Dead Until It Finds Its Target

Astellas just dropped $335 million upfront on a cancer drug that stays completely dormant until it reaches the tumor; then it wakes up and attacks. The early data on VIR-5500 is turning heads, and the deal's timing tells you everything about Astellas' post-XTANDI anxiety.